vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and Terreno Realty Corp (TRNO). Click either name above to swap in a different company.
Apellis Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($199.9M vs $137.5M, roughly 1.5× Terreno Realty Corp). Terreno Realty Corp runs the higher net margin — 115.1% vs -29.5%, a 144.6% gap on every dollar of revenue. On growth, Terreno Realty Corp posted the faster year-over-year revenue change (32.6% vs -5.9%). Over the past eight quarters, Terreno Realty Corp's revenue compounded faster (27.2% CAGR vs 7.7%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Terreno Realty Corp is a publicly traded real estate investment trust that specializes in owning, operating, and acquiring high-quality industrial real estate assets. Its portfolio mainly includes distribution warehouses and logistics facilities located in high-demand coastal U.S. metropolitan markets, serving tenants across e-commerce, last-mile delivery, retail supply chain, and light manufacturing segments.
APLS vs TRNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $137.5M |
| Net Profit | $-59.0M | $158.2M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | — |
| Net Margin | -29.5% | 115.1% |
| Revenue YoY | -5.9% | 32.6% |
| Net Profit YoY | -62.2% | 107.9% |
| EPS (diluted) | $-0.40 | $1.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | $137.5M | ||
| Q3 25 | $458.6M | $116.2M | ||
| Q2 25 | $178.5M | $112.2M | ||
| Q1 25 | $166.8M | $110.4M | ||
| Q4 24 | $212.5M | $103.7M | ||
| Q3 24 | $196.8M | $99.6M | ||
| Q2 24 | $199.7M | $94.2M | ||
| Q1 24 | $172.3M | $85.0M |
| Q4 25 | $-59.0M | $158.2M | ||
| Q3 25 | $215.7M | $103.4M | ||
| Q2 25 | $-42.2M | $93.3M | ||
| Q1 25 | $-92.2M | $48.1M | ||
| Q4 24 | $-36.4M | $76.1M | ||
| Q3 24 | $-57.4M | $36.6M | ||
| Q2 24 | $-37.7M | $35.7M | ||
| Q1 24 | $-66.4M | $36.1M |
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — | ||
| Q1 24 | -36.0% | — |
| Q4 25 | -29.5% | 115.1% | ||
| Q3 25 | 47.0% | 88.9% | ||
| Q2 25 | -23.6% | 83.1% | ||
| Q1 25 | -55.3% | 43.6% | ||
| Q4 24 | -17.1% | 73.4% | ||
| Q3 24 | -29.2% | 36.8% | ||
| Q2 24 | -18.9% | 37.9% | ||
| Q1 24 | -38.5% | 42.4% |
| Q4 25 | $-0.40 | $1.54 | ||
| Q3 25 | $1.67 | $1.00 | ||
| Q2 25 | $-0.33 | $0.90 | ||
| Q1 25 | $-0.74 | $0.47 | ||
| Q4 24 | $-0.30 | $0.78 | ||
| Q3 24 | $-0.46 | $0.37 | ||
| Q2 24 | $-0.30 | $0.37 | ||
| Q1 24 | $-0.54 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $25.0M |
| Total DebtLower is stronger | — | $943.3M |
| Stockholders' EquityBook value | $370.1M | $4.1B |
| Total Assets | $1.1B | $5.4B |
| Debt / EquityLower = less leverage | — | 0.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | $25.0M | ||
| Q3 25 | $479.2M | $26.2M | ||
| Q2 25 | $370.0M | $128.4M | ||
| Q1 25 | $358.4M | $156.5M | ||
| Q4 24 | $411.3M | $18.1M | ||
| Q3 24 | $396.9M | $243.7M | ||
| Q2 24 | $360.1M | $182.0M | ||
| Q1 24 | $325.9M | $649.6M |
| Q4 25 | — | $943.3M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $742.4M | ||
| Q1 25 | — | $741.9M | ||
| Q4 24 | — | $823.4M | ||
| Q3 24 | — | $672.2M | ||
| Q2 24 | — | $772.0M | ||
| Q1 24 | $93.1M | $771.8M |
| Q4 25 | $370.1M | $4.1B | ||
| Q3 25 | $401.2M | $4.0B | ||
| Q2 25 | $156.3M | $3.9B | ||
| Q1 25 | $164.2M | $3.9B | ||
| Q4 24 | $228.5M | $3.7B | ||
| Q3 24 | $237.1M | $3.6B | ||
| Q2 24 | $264.3M | $3.4B | ||
| Q1 24 | $266.7M | $3.4B |
| Q4 25 | $1.1B | $5.4B | ||
| Q3 25 | $1.1B | $5.3B | ||
| Q2 25 | $821.4M | $5.0B | ||
| Q1 25 | $807.3M | $4.9B | ||
| Q4 24 | $885.1M | $4.8B | ||
| Q3 24 | $901.9M | $4.6B | ||
| Q2 24 | $904.5M | $4.5B | ||
| Q1 24 | $831.9M | $4.4B |
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | 0.35× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $271.9M |
| Free Cash FlowOCF − Capex | $-14.3M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | $271.9M | ||
| Q3 25 | $108.5M | $79.5M | ||
| Q2 25 | $4.4M | $60.6M | ||
| Q1 25 | $-53.4M | $61.4M | ||
| Q4 24 | $19.4M | $232.7M | ||
| Q3 24 | $34.1M | $70.0M | ||
| Q2 24 | $-8.3M | $64.3M | ||
| Q1 24 | $-133.0M | $47.0M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | 1.72× | ||
| Q3 25 | 0.50× | 0.77× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | 1.80× | ||
| Q1 24 | — | 1.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TRNO
| Disposal Group Disposed Of By Sale Not Discontinued Operations | $109.5M | 80% |
| Other | $23.8M | 17% |
| At Market Equity Offering Program500Million | $4.1M | 3% |
